We next combined EO05, a very well characterized EO from Melaleuca alternifolia33 containing all the three components identified through the ML approach, with the targeted therapy currently used for the treatment of advanced melanoma patients harboring BRAF mutations34. Here, BRAF is linked to melanoma.